Since 2000 the model has well captured the steady-to- cooling trend shown in temperature data, while all IPCC GCMs have failed the prognosis by predicting steady warming.
Patients whose cancers are churning out the Sparc protein usually have a worse prognosis than those who aren't Sparc-positive, but with Abraxane they may do just as well, Soon-Shiong argues.